5.32
0.08 (1.53%)
| Penutupan Terdahulu | 5.24 |
| Buka | 5.26 |
| Jumlah Dagangan | 122,522 |
| Purata Dagangan (3B) | 308,558 |
| Modal Pasaran | 300,392,384 |
| Harga / Jualan (P/S) | 78.86 |
| Harga / Buku (P/B) | 6.87 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2025 |
| Margin Operasi (TTM) | -2,179.84% |
| EPS Cair (TTM) | -1.77 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 40.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 97.55% |
| Nisbah Semasa (MRQ) | 3.35 |
| Aliran Tunai Operasi (OCF TTM) | -54.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.16 M |
| Pulangan Atas Aset (ROA TTM) | -60.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -179.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Orchestra BioMed Holdings, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.30 |
|
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 21.81% |
| % Dimiliki oleh Institusi | 49.62% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 20.00 (Chardan Capital, 275.94%) | Beli |
| Median | 15.50 (191.35%) | |
| Rendah | 11.00 (Barclays, 106.77%) | Beli |
| Purata | 15.50 (191.35%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 4.30 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 13 Nov 2025 | 20.00 (275.94%) | Beli | 4.18 |
| Barclays | 12 Nov 2025 | 11.00 (106.77%) | Beli | 4.42 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SHERMAN DARREN | - | 5.35 | -40,340 | -215,819 |
| TAYLOR ANDREW LAWRENCE | - | 5.35 | -3,071 | -16,430 |
| Jumlah Keseluruhan Kuantiti Bersih | -43,411 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -232,249 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 5.35 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SHERMAN DARREN | Pegawai | 25 Nov 2025 | Dibuang (-) | 40,340 | 5.35 | 215,819 |
| TAYLOR ANDREW LAWRENCE | Pegawai | 25 Nov 2025 | Dibuang (-) | 3,071 | 5.35 | 16,430 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Nov 2025 | Pengumuman | Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 11 Nov 2025 | Pengumuman | Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences |
| 10 Nov 2025 | Pengumuman | Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates |
| 03 Nov 2025 | Pengumuman | Orchestra BioMed to Host Business Update Call on November 12, 2025 |
| 28 Oct 2025 | Pengumuman | Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements |
| 27 Oct 2025 | Pengumuman | Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial |
| 09 Oct 2025 | Pengumuman | Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |